Taxanes induced neuropathy

Evidence-based neurology checklist on taxanes induced neuropathy: Types of taxanes Paclitaxel Docetaxel nab-Paclitaxel Mechanism of action Risks of neuropathy Clinical features of neuropathy Management Investigational preventative treatments

Types of taxanes

  • Paclitaxel
  • Docetaxel
  • nab-Paclitaxel 

Mechanism of action

Risks of neuropathy

Clinical features of neuropathy

Management

Investigational preventative treatments

References

  1. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 2015; 75:659-670.
  2. Kudlowitz D, Muggia F. Clinical features of taxane neuropathy. Anticancer Drugs 2014; 25:495-501.
  3. Song SJ, Min J, Suh SY, et al. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer 2017; 25:2241-2248. 
  4. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol 2008; 66:218-228. 
  5. Nurgalieva Z, Xia R, Liu CC, Burau K, Hardy D, Du XL. Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. Am J Ther 2010; 17:148-158.
  6. And 3 more. Subscribe to see the full list

Related checklists

Loading...